By analyzing gene expression datasets from breast cancer patients treated with neoadjuvant targeted or chemotherapy (Creighton et al., 2009; Stickeler et al., 2011), we show here that CCL5 expression is elevated in residual tumor cells that survive therapy. This evidence concerns the gene CCL5 and breast cancer.